Organization
Guangzhou Medical University Cancer Center, Guangzhou, China
3 abstracts
Abstract
Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.Org: Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China, Guangzhou Medical University Cancer Center, Guangzhou, China, Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Radiation Oncology, The Central Hospital of Shaoyang, Shaoyang, Hunan, China,
Abstract
Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangzhou Institute of Respiratory Health, National Cancer Institute, Vilnius, Lithuania,
Abstract
Respiratory toxicities after concurrent chemoradiotherapy and subsequent consolidation immune checkpoint inhibitors in locally advanced non-small cell lung cancer: Infectious and non-infectious subtypes by pathogen NGS testing.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Cardiac Surgery, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,